Overview

  • Product nameAnti-CHST3 antibody
    See all CHST3 primary antibodies
  • Description
    Mouse monoclonal to CHST3
  • Tested applicationsSuitable for: WBmore details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Recombinant fragment: VAFAGKYKTW KKWLDDEGQD GLREEEVQRL RGNCESIRLS AELGLRQPAW LRGRYMLVRY EDVARGPLQK AREMYRFAGI PLTPQVEDWI QKNTQAAHDG , corresponding to amino acids 312-412 of Human CHST3

Properties

Applications

Our Abpromise guarantee covers the use of ab56606 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB
  • Application notesWB: Use at a concentration of 1-5 µg/ml.


    Not yet tested in other applications.
    Optimal dilutions/concentrations should be determined by the end user.
  • Target

    • FunctionCatalyzes the transfer of sulfate to position 6 of the N-acetylgalactosamine (GalNAc) residue of chondroitin. Chondroitin sulfate constitutes the predominant proteoglycan present in cartilage and is distributed on the surfaces of many cells and extracellular matrices. Can also sulfate Gal residues of keratan sulfate, another glycosaminoglycan, and the Gal residues in sialyl N-acetyllactosamine (sialyl LacNAc) oligosaccharides. May play a role in the maintenance of naive T-lymphocytes in the spleen.
    • Tissue specificityWidely expressed in adult tissues. Expressed in heart, placenta, skeletal muscle and pancreas. Also expressed in various immune tissues such as spleen, lymph node, thymus and appendix.
    • Involvement in diseaseDefects in CHST3 are a cause of spondyloepiphyseal dysplasia with congenital joint dislocations (SEDC-JD) [MIM:143095]. A bone dysplasia clinically characterized by dislocation of the knees and/or hips at birth, clubfoot, elbow joint dysplasia with subluxation and limited extension, short stature, and progressive kyphosis developing in late childhood. The disorder is usually evident at birth, with short stature and multiple joint dislocations or subluxations that dominate the neonatal clinical and radiographic picture. During childhood, the dislocations improve, both spontaneously and with surgical treatment, and features of spondyloepiphyseal dysplasia become apparent, leading to arthritis of the hips and spine with intervertebral disk degeneration, rigid kyphoscoliosis, and trunk shortening by late childhood.
    • Sequence similaritiesBelongs to the sulfotransferase 1 family. Gal/GlcNAc/GalNAc subfamily.
    • Cellular localizationGolgi apparatus membrane.
    • Information by UniProt
    • Database links
    • Alternative names
      • C6ST 1 antibody
      • C6ST antibody
      • C6ST-1 antibody
      • C6ST1 antibody
      • Carbohydrate (chondroitin 6) sulfotransferase 3 antibody
      • Carbohydrate sulfotransferase 3 antibody
      • Chondroitin 6 O sulfotransferase 1 antibody
      • Chondroitin 6 sulfotransferase antibody
      • Chondroitin 6-O-sulfotransferase 1 antibody
      • Chondroitin 6-sulfotransferase antibody
      • CHST 3 antibody
      • Chst3 antibody
      • CHST3_HUMAN antibody
      • Galactose/N acetylglucosamine/N acetylglucosamine 6 O sulfotransferase 0 antibody
      • Galactose/N-acetylglucosamine/N-acetylglucosamine 6-O-sulfotransferase 0 antibody
      • GST 0 antibody
      • GST-0 antibody
      • GST0 antibody
      see all

    Anti-CHST3 antibody images



    • Predicted band size : 55 kDa
      CHST3 antibody (ab56606) at 1ug/lane + HeLa cell lysate at 25ug/lane.

    References for Anti-CHST3 antibody (ab56606)

    ab56606 has not yet been referenced specifically in any publications.

    Product Wall

    There are currently no Abreviews or Questions for ab56606.
    Please use the links above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"